LABCORP HOLDINGS INC

Labcorp plans an Investor Day to reveal its capital strategy and growth roadmap, highlighting genomics, AI diagnostics, and regulatory navigation.

SureNano Science’s latest update details its GLP‑1 peptide pipeline, surfactant platform revenue, and critical funding needs amid growing losses.

Labcorp’s Q2 2026 earnings show a 3.2 % revenue rise, 13.6 % margin boost, and an upward full‑year outlook, driven by oncology expansion and consumer‑health AI tools.

Labcorp & OpenAI launch AI‑powered lab analytics, boosting accuracy, cutting turnaround, and driving new revenue – a game‑changer for clinical labs.

Labcorp’s new $0.35 quarterly dividend and expanded DPYD pharmacogenomic testing underline its dual focus on shareholder returns and precision medicine advancements, boosting patient safety and cost‑efficiency.

Labcorp Holdings Inc. (LH) confirms Q2 2026 earnings will be released July 30, highlighting regulatory compliance, global reach, and insider activity.

Investigate LABCORP’s CS/CO resignation: regulatory impact, investor sentiment, and competitive risk—why this move matters for governance and market confidence.

Labcorp’s Q1 2026 earnings show steady 2 % revenue growth, solid gross margins and disciplined SG&A, positioning the lab giant for AI‑driven diagnostics and value‑based reimbursement success.

Labcorp’s Bengaluru lease boosts diagnostics, data‑analytics, and value‑based care in India’s fastest‑growing healthcare hub.

Labcorp’s rise to the S&P 500 spot and launch of the PD‑L1 IHC 22C3 assay signal a new era of integrated oncology diagnostics and data‑driven precision medicine, driving growth and competitive advantage.